that specifically phosphorylate pocket proteins as for instance the tumor-suppressor protein pRb or its relatives p107 or p130 (for a review see Morgan, 1995; Bartek et al., 1996; Planas-Silva and Weinberg, 1997) . Once phosphorylated, these pocket proteins are released from a complex with the E2F group of transcription factors that regulate the expression of S-phase-specific genes (for a review see Weinberg, 1996) . D-and E-type cyclins and the kinases Cdk4, Cdk6 and Cdk2 are the most important molecules involved at this regulatory checkpoint late in G1 that is also termed restriction point. The expression of G1-specific cyclins that are necessary for full Cdk activity depends on external signals mediated by growth factors and mitogens and decreases when signals for cell divisions are not maintained or when cells have progressed through the restriction point into S phase (Sherr and Roberts, 1995; Weinberg, 1996; Sherr, 1996) . The activity of cyclin/Cdk complexes as kinases is decreased or blocked by a number of inhibitors called CKIs (Cdk inhibitors, for a review see Sherr and Roberts, 1995; Harper and Elledge, 1996) . Of particular importance in this respect are the proteins p16 INK4a , p21 Waf1 , and p27 Kip1 (Polyak et al, 1994; Hall et al., 1995; Reynisdottir et al., 1995; Sherr and Roberts, 1995; Harper and Elledge, 1996; Sherr, 1999) . Both p21
Waf1 and p27 Kip1 bind to cyclin E/Cdk2 or cyclin D/Cdk4 complexes and block their activities, whereas p16
Ink4a exclusively interacts with Cdk4 and Cdk6, which are the specific catalytic subunits of D-type cyclins (Ruas and Peters, 1998) .
To date, several lines of evidence indicate that the regulation of G1/S transition at the restriction point is a critical event for mammalian cells (Sherr, 1996; Hanahan and Weinberg, 2000) . Failure in the regulatory network that controls the restriction point can provoke a derailment of cells with the eventual consequence of malignant transformation. A constitutive, unregulated expression of D-or E-type cyclins or in some cases Cdks can lead to the malignant transformation of primary rodent fibroblasts in culture when other transforming events are present, as for instance the activated forms of the protooncoproteins Ha-ras or Ki-ras (Lovec et al., 1994b; Galaktionov et al., 1995; Haas et al., 1997a, b; Karsunky et al., 1999) . A view of G1-specific cyclins as classical dominant oncogenes was also supported by the finding that D-or E-type cyclins are overexpressed in a variety of human tumors (for a review see Weinberg et al., 1996) , and that a targeted expression of cyclins in transgenic mice can predispose these animals for the development of malignant diseases albeit at a weak level or only in cooperation with other oncogenic events (Bodrug et al., 1994; Lovec et al., 1994b; Bortner and Rosenberg, 1997) . Of particular interest for the pathogenesis of leukemia and lymphoma was the finding that cyclin E is expressed at high levels in several types of leukemias, in chronic lymphocytic leukemia, Hodgkin's and Non-Hodgkin's lymphoma (Erlanson et al., 1998; Erlanson and Landberg, 2001 ; for a review see Hall and Peters, 1996; Donnellan and Chetty, 1999) . Along the same line, the loss of the negative cell cycle regulators p21 Waf1 or p27 Kip1 had been suspected to play a role in the initiation of malignant transformation (Slingerland and Pagano, 2000) . Low levels of p27
Kip1 and high levels of cyclin E were found to be significantly associated with a poor prognosis of malignant lymphoma (Erlanson et al., 1998) , but neither p21
Waf1
-nor p27 Kip1 -deficient mice develop spontaneous lymphoid malignancies, arguing against a role of these proteins as tumor suppressors in lymphomagenesis (Deng et al., 1995; Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . However, when p27
Kip1
-deficient mice are treated with carcinogens such as ethyl-nitroso-urea (ENU), they succumb to epithelial-type tumors with higher rates and shorter latency periods than normal control mice (Fero et al., 1998) . Moreover, loss of p27
Kip1 provokes the emergence of prostate cancer in pten-deficient mice, illustrating a cooperative effect of the absence of p27 Kip1 with the loss of another tumor suppressor (Di Cristofano et al., 2001) .
We had previously established a transgenic mouse model in which high levels of ectopically expressed human cyclin E was targeted to the T-lymphoid lineage by the CD2 promoter. These CD2-cyclin E transgenic animals were significantly more susceptible to the induction of T-cell lymphomas upon treatment with methyl-nitroso-urea (Karsunky et al., 1999) . However, without treatment these animals never succumbed to Tcell lymphoma; in this respect they behave similar as animals lacking p27 Kip1 . Thus, we speculated that lack of p27
Kip1 or the overexpression of cyclin E as a single factor is insufficient to deregulate severely the restriction point control possibly because of compensating events. We therefore wished to investigate whether such a compensation is still possible in cells facing the loss of p27
Kip1 and a concurrent constitutive expression of cyclin E and whether both events are sufficient to predispose animals for the formation of spontaneous lymphoid tumors.
To answer this question, we have set up crossbreedings between CD2-cyclin E transgenic animals and p27 Kip1 -deficient mice. In extracts from thymocytes we observed, as expected, expression of the human cyclin E in those animals bearing the CD2-cyclin E transgene and p27
Kip1 expression in all animals except those with a targeted deletion of the p27 Kip1 gene ( Figure 1 ). Only in thymocytes from animals lacking p27
Kip1 and simultaneously carrying the CD2-cyclin E transgene, we were able to detect a significantly higher level of histone H1 phosphorylation compared to cells from single transgenics or wilde-type(wt) animals ( Figure 1 ). Expression levels of pRb were not noticeably altered but the pRb protein from CD2-cyclin E/p27 Kip1 thymocytes appeared to have a slightly higher molecular weight (Figure 1 ), pointing to a higher degree of phosphorylation. These findings suggest that the combination of high constitutive levels of cyclin E in the absence of p27
Kip1 can deregulate the restriction point control in primary thymocytes to an extent that results in a higher kinase activity at the G1 restriction point and possibly a higher degree of pocket protein phosphorylation.
Next, we stained thymocytes from wt and combinatorial mouse mutants at the age of 6-10 weeks and with no signs of malignancies with Hoechst 33382 or propidium iodide to measure the percentage of cells in the different cell cycle phases. We had previously described that thymocytes from CD2-cyclin E transgenic mice only show very small or no alteration of these parameters (Karsunky et al., 1999) . Thymocytes from Extracts from thymocytes of animals with the indicated genotypes were separated by SDS-PAGE and the expression of the human cyclin E transgene or the endogenous p27 Kip1 or pRb proteins was detected by specific antibodies (p27 Kip1 (C-19, Santa Cruz), human cyclin E (C-19 or HE12, Santa Cruz)), p27
Kip1 (DCS-72, generously provided by J Bartek) and pRb (G3-245, Pharmingen). Protein lysate concentrations were determined by Bradford assay and equal amounts of proteins were used for Western blotting (30 mg) and kinase assays (200 mg). Immunoprecipitations from these extracts with an anti-Cdk2 antibody were used in a kinase assay with histone H1 as a substrate as described previously (Geisen and Mo¨ro¨y, 2002) . The phosphorylated complexes were separated by SDS-PAGE and revealed by autoradiography. We observed as described before (Geisen and Mo¨ro¨y, 2002 ) that in many cases the expression of cyclin E led to the appearance of a predominant band of the expected molecular weight in Western blots (arrowheads), as well as different faster migrating immunoreactive bands, suggesting either post-translational modification, degradation or alternative translation from a second start codon
-deficient mice show a moderate increase of cells in cycle and a slightly higher level of histone H1 phosphorylation than wt or CD2-cyclin E transgenic mice (Figures 1 and 2) . However, in p27 Kip1 -deficient mice that carry the CD2-cyclin E transgene significantly more T cells were in S/G2/M phases (Figure 2a, b) , indicating a marked acceleration of cell cycle progression. In addition, T cells from CD2-cyclin E/p27
Kip1À/À mice showed the highest degree of histone H1 phosphorylation when compared to p27 Kip1 -deficient cells or to cells from CD2-cyclin E transgenic or wt mice (Figure 1) .
Six of eight CD2-cyclin E/p27
Kip1À/À animals that could be observed over a time period of over 400 days succumbed with lymphoid neoplasia predominantly in the spleen with occasional participation of lymph nodes (Figure 3) . The average latency period for the development of these neoplasia was 311 days. In this same time frame, none of the p27 Kip1 -deficient mice (Figure 3) or as previously reported (Karsunky et al., 1999) none of the single CD2-cyclin E transgenic mice developed any type of malignancy even when one allele of the p27
Kip1 gene was deleted (Karsunky et al., 1999 and data not shown). Closer analysis of the tumors revealed that they were derived from the T-cell lineage, since none of the cells from the tumors stained positive for the B-cell marker B220, but all were positive for either the CD4 or CD8 co-receptor and for the T-cell marker Thy-1 (Table 1, Figure 4 ). Distinct V(D)J rearrangement events were detectable in the genomic DNA from these neoplastic lymphoid tissues with a probe from the TCRb locus (Jb2), which supported the T-cell type of the tumors and indicated the clonality of the cells (Figure 4 ). Both the characterization of the cell surface markers and the clonality of the cells directly demonstrate that the observed neoplastic tissues in CD2-cyclin E/p27 Kip1À/À transgenic animals are indeed malignant T-cell lymphomas.
These findings provide further experimental evidence that the deregulation of the restriction point in the late G1 phase of the cell cycle is critical for the development of malignant diseases and, in particular, can be a prerequisite for lymphomagenesis. Mice that are deficient for p27
Kip1 display altered growth characteristics but do not develop any overt malignant tumor with the 
Kip1À/À mice (n ¼ 6). For cell cycle analysis with Hoechst 33382, cells were pelleted, washed once with cold PBS, resuspended in 500 ml PBS/1% FCS and mixed with 5 ml of a solution of Hoechst 33382 dye (1 mg/ml). Cells were kept for 30 min at 371C and were subsequently analysed using a FACSVantage and Cellquest software (Becton Dickinson). Propidium iodide staining was performed as previously described (Karsunky et al., 1999) . Kip1À/À and CD2-cyclin E/p27
Kip1À/À animals. The percentage of tumor-free animals is plotted against their age in weeks p27 Kip1À/À control animals n ¼ 13, CD2-cyclin E/ p27
Kip1À/À animals, n ¼ 8. CD2-cyclin E transgenic mice as well as p27
Kip1 -deficient animals have been described before (Fero et al., 1996; Karsunky et al., 1999) and were kept by crossbreeding with C57Bl/6 animals. Animals were housed under specific pathogenfree conditions. Preparation and analysis of genomic DNA from tail tips and tumor samples were performed as previously described (Hogan et al., 1994) . DNA blotting procedures were performed as described elsewhere (Sambrook et al., 1989) Cooperation of cyclin E and p27 kip1 C Geisen et al exception of neoplasia of the pituitary (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . A potential role of p27
Kip1 as a tumor suppressor is consistent with the sensitivity of p27 However, none of these experimental settings supported a role of p27 Kip1 in lymphomagenesis although the numbers of lymphoid cells in thymus and spleen of p27 Kip1 -deficient mice are dramatically increased; thus, in particular, the emergence of T-cell lymphoma in these animals would have been expected. Our findings presented here clearly demonstrate that loss of p27 Kip1 can predispose for the development of such lymphoid neoplasms, but also indicate that other cooperating events are necessary such as the deregulation of a positive G1 regulator. Interestingly, we do not observe haploinsufficiency of p27
Kip1 in contrast to the findings reported by Fero et al. (1998) where carcinogen-treated p27 Kip1+/À animals developed tumors. Most recently, two different groups have used p27
Kip1 KO mice for an Characterization of tumors that arose in populations of CD2-cyclin E/p27 Kip1À/À combinatorial mutant mice. The rearrangements of the T-cell receptor b locus (Jb2 R ) were determined by Southern blot analysis of DNA directly prepared from tumor tissue using the Jb2 probe as described before (Mo¨ro¨y et al., 1990) . Single-cell suspensions from tumor samples were stained with directly labeled antibodies for Thy-1.2, B220, CD4 and CD8 surface markers according to standard procedures. Tumors in CD2-cyclin E/p27 Kip1À/À mice are of T-cell origin. (a) Cells from tumorous tissue were prepared and stained with directly labeled antibodies against the cell surface markers B220, Thy-1, CD4 and CD8. An example of one tumor is shown that expresses the CD8 and Thy-1. Single-cell suspensions were prepared as described (Mo¨ro¨y et al., 1993) at the time of autopsy from thymus or tumor tissue in PBS supplemented with 0.5% FCS (staining solution). Cells were washed in this solution and incubated on ice for 30 min with antibodies directly conjugated with fluorochromes (all antibodies supplied from Pharmingen). Cells were washed twice in staining solution after the incubation and examined with a FACSCalibur (Becton-Dickinson). (b) Genomic DNA was extracted from tumor cells and after restriction enzyme digestion and Southern blotting, hybridized with the Jb2 probe derived from the TCRb locus. The Jb2 probe that was used to detect TCRb rearrangements is a 1.9 kb HindIII-BamHI fragment containing the J locus as described (Mo¨ro¨y et al., 1990) . Whereas control DNA from fibroblasts does not reveal any rearrangement at this locus, the DNA from tumors 3 and 5 retains one allele unrearranged and shows a rearrangement on the second TCR b allele. DNA from tumors 1 and 2 had lost the germline configuration on both TCR alleles infection with the nonacute transforming retrovirus of the Moloney type (MoMuLV), which almost exclusively provokes the outgrowth of T-cell tumors Martins and Berns, 2002) . The analysis of the Tcell lymphoma that emerged after the infection demonstrated that MoMuLV-induced T-cell tumorigenesis was markedly accelerated in p27
Kip1 deficient, mice, also supporting a role of this inhibitor in lymphomagenesis. Interestingly, a high proportion of p27
Kip1
-negative Tcell tumors showed an activation of the Myc gene through proviral insertion demonstrating a cooperation between the loss of p27 Kip1 and Myc activation. It is long established that Myc functions as a dominant oncogene mainly through its ability to accelerate progression of cells through G1 into S phase (for a review see Lu¨scher, 2001) . In this respect, Myc and cyclin E have similar roles but the molecular mechanisms of a cooperation between the provirally targeted Myc gene or a cyclin E gene overexpressed through transgenesis and the absence of p27
Kip1 are different. In the former case, both the activation of Myc and the loss of p27
Kip1 enhance Cdk2 activity and progression through G1 independently as single events. In contrast, cyclin E overexpressing T cells from CD2-cyclin E transgenic mice do not display elevated Cdk2 kinase activity, instead, the level of endogenous p27 Kip1 rises in these cells (Karsunky et al., 1999) . It is conceivable that a stabilization of newly synthesized p27
Kip1 through increased concentration of cyclin E protein takes place in these cells, rather than a decrease of p27
Kip1 protein levels through increased phosphorylation by cyclinE/Cdk2. According to a recent report, the lack of elevated Cdk2 activity in cells with high constitutive levels of cyclin E is because of the activation of a p53-dependent pathway and the upregulation of p21
Waf1 (Minella et al., 2002) . As a consequence, T cells from CD2-cyclin E transgenic mice have no marked increase of their proliferative rate and need an additional mitogenic event that affects other G1 regulator proteins. If this is provided for instance indirectly through an activated Ki-ras gene or the loss of p27 Kip1 , the consequences of a cyclin E-mediated p53 activation could be circumvented with the result that T-cell tumors emerge.
